Teijin Acquires Global Structure Database Management Licenses and Switches Over to JChem Platform

    BUDAPEST, Hungary and TOKYO, Japan, September 5 /PRNewswire/ --
 ChemAxon and Teijin Pharma Ltd. announced the acquisition of ChemAxon's
 database structure management and search toolkits and the switch over of
 Teijin Pharma's chemical information platform to operate with ChemAxon's
 JChem technology.
     The provision will see Teijin Pharma, a medical and pharmaceuticals
 business subsidiary of Teijin, update their existing system for archiving
 small molecules by implementing the JChem platform. The JChem platform will
 better enable Teijin to develop more powerful solutions for Teijin's
 research activities worldwide. The adoption of the JChem platform for small
 molecule storage and search constitutes a step forward in this process.
     "We are pleased with the performance and potential of the JChem tools
 in our system, the functions are particularly suitable for distributed,
 enterprise class solutions," commented Dr. Hiroshi Kawabata, Ph.D., Senior
 Manager, Medicinal Chemistry Research Department, Pharmaceutical Discovery
 Research Laboratories at Teijin Pharma Limited.
     "We are very happy that our science and functionality is relevant to
 Teijin, particularly given its scale and scope. Commercially we believe
 that this switch may fully open the door for further adoptions in Japan and
 would mirror our experience with clients globally," commented Dr Ferenc
 Csizmadia, CEO of ChemAxon.
     About ChemAxon
     ChemAxon is a leader in providing cheminformatics software development
 platforms and applications for the biotechnology, pharmaceutical and
 agrochemical industries. With core capabilities for structure
 visualization, search and management, property prediction, virtual
 synthesis, screening and drug design, ChemAxon focuses upon active
 interaction with users and software portability to create powerful, cost
 effective cross platform solutions and programming interfaces to power
 modern cheminformatics and chemical communication. For more information
 visit http://www.chemaxon.com/
     About Teijin Group and its Pharmaceutical subsidiary
     The Teijin Group (http://www.teijin.co.jp/english/flash.html) is active
 in a wide range of businesses, including fibers, films, plastics,
 pharmaceuticals and home health care and information technology
 (IT)-related services.
     Teijin Pharma (http://www.teijin-pharma.co.jp/english/index.html),
 medical and pharmaceuticals business subsidiary of Teijin, focuses on the
 three key therapeutic areas: respiratory, bone/joint, and
 cardiovascular/metabolic diseases. In the respiratory field, Teijin Pharma
 has strong R&D and marketing position with pharmaceutical products and home
 oxygen therapy (HOT) business, which has a top market share in Japan.
 Teijin Pharma is now trying to expand its product pipeline for COPD/asthma
 by in-licensing as well as in-house R&D; it will continue to pursue
 providing total health care services for these patients through synergistic
 activities in the pharmaceuticals and HOT businesses.
 
 

SOURCE ChemAxon Ltd.